Irvine, CA (PRWEB) March 06, 2014
Proove Biosciences, the leader Personalized Pain Medicine testing services, will participate and present clinical data and research at the American Academy of Pain Medicine’s 30th annual meeting this weekend, March 6-9, 2014. The meeting provides a comprehensive overview and review of current and cutting-edge pain medicine practice topics.
AAPM President and Proove Medical Advisory Board Member, Dr. Lynn Webster, will be moderating a workshop on safe opioid prescribing practices. The program will educate prescribers about eight evidence-based principles that will drastically reduce the number of unintentional overdose deaths from prescription medication.
"We are thrilled to be a part of the AAPM’s Annual Meeting. As the premiere industry forum, we are excited to share and present our clinical data on how our Proove Genetic tests have been helping pain medicine professionals throughout the country improve the selection, dosing, and evaluation of medications. We will exhibit how Proove helps identify patients at risk for tolerance and misuse of medications, and how we have been creating efficiency within the healthcare system, while improving safety and decreasing risks associated with pain medicine therapies," stated Brian Meshkin, President of Proove Biosciences.
Proove will again be the only company presenting data on the genetics of pain medicine. During the poster session, Proove will be presenting data correlating genetic variations with co-occurring psychiatric disorders among chronic pain patients taking narcotics.
About the American Academy of Pain Medicine
The American Academy of Pain Medicine (AAPM) is the medical specialty society representing physicians practicing in the field of pain medicine. As a medical specialty society, the Academy is involved in education, training, advocacy, and research in the specialty of pain medicine.
About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).